Search Results 1001-1010 of 17592 for Assay

1. A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors - Mayo Clinic

   ... assays and in vivo animal models. Kumar S. Sujatha; Ghosh S. Srimoyee; Sharma G. Geeta; Wang Z. Zebin; Kehry MR. Marilyn R; Marino MH. Margaret H; Neben TY ...

2. TN-401, A Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Plakophilin-2 (PKP2) Transgene, In Adults With PKP2 Mutation-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) - Mayo Clinic

   Latent tuberculosis infection defined as positive interferon gamma release assay (IGRA), by QuantiFERON-TB Gold testing at Screening. History of clinically ...

3. A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   Serum free light chain assay: involved free light chain level ≥ 10 mg/dL ( ≥ 100 mg/L), provided that the serum free light chain ratio is abnormal.

4. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer - Mayo Clinic

   ctDNA assay must be performed through this trial or study BNT000-001 ctDNA screening protocol. * Patients must have an Eastern Cooperative Oncology Group ...

5. PR3-AAV Resilient Remission or PRRR - Mayo Clinic

   - Positive serum assays for ANCA directed against myeloperoxidase (MPO-ANCA) - Non-severe AAV, defined as disease that does not justify treatment with both ...

6. Publications - David S. Viswanatha, M.D. - Mayo Clinic

   A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia. Blood Adv. 2022 Feb 8; 6 (3): ...

7. Yang You, Ph.D. - Mayo Clinic Faculty Profiles

   By combining CRISPR-engineered iPSC lines, comprehensive EV profiling and functional assays, his team seeks to uncover EV-dependent mechanisms that can be ...

8. Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant - Mayo Clinic

   Patient has a pathology report confirming PIK3CA mutant status by a certified laboratory using a validated PIK3CA mutation assay (either from tissue or blood).

9. A Study to Evaluate M7824 with Concurrent Chemoradiation (cCRT) in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

   The primary purpose of this study is to evaluate safety and effectiveness in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 ...

10. A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis - Mayo Clinic

    Documented positive AMA titer (> 1:40 titer on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay) or PBC-specific ANA immuno ...